Last reviewed · How we verify
Isavuconazonium sulfate IV
At a glance
| Generic name | Isavuconazonium sulfate IV |
|---|---|
| Also known as | Cresemba |
| Sponsor | Astellas Pharma Global Development, Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Trial of Novel Anti-leukemia Agents in Flu/Mel RIC Transplant for Myeloid Malignancies (PHASE1)
- Imetelstat Combinations in Relapsed AML (PHASE1)
- Study of Biomarker-Based Treatment of Acute Myeloid Leukemia (PHASE1, PHASE2)
- Liposomal Amphotericin B Plus Posaconazole/Isavuconazole for Mucormycosis in Hematologic Malignancies: Efficacy and Safety
- Liposomal Amphotericin B and Isavuconazole/Posaconazole in Br-IFD（ Breakthrough Invasive Fungal Disease） in Patients With Malignant Hematological Diseases
- Isavuconazole in the Treatment of Renally Impaired Aspergillosis and Rare Fungi (PHASE3)
- Isavuconazole (BAL8557) in the Treatment of Candidemia and Other Invasive Candida Infections (PHASE3)
- Isavuconazole (BAL8557) for Primary Treatment of Invasive Aspergillosis (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Isavuconazonium sulfate IV CI brief — competitive landscape report
- Isavuconazonium sulfate IV updates RSS · CI watch RSS
- Astellas Pharma Global Development, Inc. portfolio CI